Difference between revisions of "Talk:P16"

From Libre Pathology
Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 9: Line 9:


== More on p16 in oral sites==
== More on p16 in oral sites==
p16 in oral sites usually not HPV driven. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836441/
*p16 in oral sites usually not HPV driven. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836441/
 
== Cutaneous SCC ==
*p16 positive in ~ 1/3 cases - https://pubmed.ncbi.nlm.nih.gov/28663082/
 
== p16 UCC ==
https://pubmed.ncbi.nlm.nih.gov/20164052/
 
== p16 +ve H&N SqCC vs Lung Primary ==
 
<pre>
Lung primaries are commonly positive for p16[1]; thus, p16 CANNOT be used to reliably differentiate between p16 positive head and neck cancers and lung cancer.
 
1. Br J Cancer. 2000 Jan;82(2):374-80. doi: 10.1054/bjoc.1999.0929. https://pubmed.ncbi.nlm.nih.gov/10646891/
https://doi.org/10.1054/bjoc.1999.0929
</pre>

Latest revision as of 19:55, 18 December 2022

p16 non-oropharyngeal sites

ENT surgeons may over interpret p16 staining in non-oropharyngeal sites. This disclaimer may be useful:

Note: 
p16 staining in non-oropharyngeal sites is nonspecific in a diagnostic context.


More on p16 in oral sites

Cutaneous SCC

p16 UCC

https://pubmed.ncbi.nlm.nih.gov/20164052/

p16 +ve H&N SqCC vs Lung Primary

Lung primaries are commonly positive for p16[1]; thus, p16 CANNOT be used to reliably differentiate between p16 positive head and neck cancers and lung cancer.

1. Br J Cancer. 2000 Jan;82(2):374-80. doi: 10.1054/bjoc.1999.0929. https://pubmed.ncbi.nlm.nih.gov/10646891/
https://doi.org/10.1054/bjoc.1999.0929